Celldex Therapeutics (CLDX) to Present ReACT Study Data at 2015 ASCO Annual Meeting
Tweet Send to a Friend
Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
